Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical has secured firm commitments for an $8 million capital raising, comprising a $6 million two-tranche placement to institutional and professional investors and a fully underwritten $2 million non-renounceable entitlement offer, both priced at $0.68 per share with attaching options. The raise, backed by substantial shareholders including Pengana High Conviction Equities Fund and with participation from directors, will lift pro forma cash to about $12 million to fund ongoing commercial roll-out, regulatory activities and key clinical milestones, notably a German government-sponsored G-BA trial involving around 40 hospitals set to begin recruiting in the first half of 2026, expected to generate trial-related revenues and support broader European reimbursement and guideline inclusion, while momentum continues in other European markets and label expansion submissions progress.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is an Australian-listed medical device company focused on developing and commercialising the OncoSil™ brachytherapy device for the treatment of pancreatic cancer. The company is targeting key European markets including Germany, Spain, Italy and Turkey, where it is building a network of implanting centres and pursuing label expansions and reimbursement to strengthen its position in oncology treatment pathways.
Average Trading Volume: 24,813
Technical Sentiment Signal: Sell
Current Market Cap: A$15.11M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.